Cellenkos' umbilical cord blood-derived T regulatory cell therapy significantly slowed ALS disease progression, reducing monthly ALSFRS-R score decline from -1.66 to -0.41 points during treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.